Dyne Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$468.2M | -$343.9M | -$242.2M | -$171.0M | -$150.0M |
| Operating expenses | $468.2M | $343.9M | $242.2M | $171.0M | $150.0M |
| Cash from operations | -$403.2M | -$292.4M | -$188.2M | -$153.6M | -$119.6M |
| Capital expenditure | $1.9M | $2.4M | $729,000 | $3.1M | $3.6M |
| Free cash flow | -$405.1M | -$294.7M | -$188.9M | -$156.7M | -$123.2M |
| Impairments | — | — | — | — | $0 |
| Total assets | $1.2B | $691.2M | $165.1M | $306.3M | $425.7M |
| Total liabilities | $214.8M | $61.4M | $73.8M | $54.0M | $57.5M |
| Total debt | $150.0M | — | — | — | — |
Shares outstanding 113.1M · Free float 91.7%
Annual filing data through FY ended December 31, 2025; float as of July 4, 2026.